CTCFL and ovarian carcinoma: BORIS is ectopically expressed in other malignancies including glioblastoma [43], melanomas [44], head and neck squamous cell carcinoma [45], esophageal cancer [46], breast cancer [47], prostate cancer [48], uterine corpus cancer [49] and ovarian cancer [50], and BORIS might be a reasonable candidate for immunotherapies of those malignancies.